A Phase I Study of Extended Infusion Carfilzomib on a Weekly Schedule in Patients With Advanced Solid Malignancies
Phase of Trial: Phase I
Latest Information Update: 20 Apr 2017
Price : $35 *
At a glance
- Drugs Carfilzomib (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Onyx Pharmaceuticals
- 03 Feb 2017 Status changed from recruiting to completed.
- 07 Nov 2016 Planned End Date changed from 1 Feb 2017 to 1 Aug 2017.
- 07 Nov 2016 Planned primary completion date changed from 1 Feb 2017 to 1 Aug 2017.